We focused here on thyroid carcinomas where higher CD47 expression is associated with improved outcomes, but the stronger associations of higher IFT57 mRNA with poorer survival in lung squamous carcinoma, glioma, and head and neck squamous carcinoma raise concern that the previous studies attributing impaired survival of cancers with higher CD47 expression exclusively to its ‘don’t eat me’ function should also consider the role of the coexpressed IFT57 in patient survival and responses to therapy [3,4,5,6]. The gene discussed is IFT57; the disease is thyroid gland carcinoma.